Jean-Pierre Brion

Director of LHNN, Professor

Université libre de Bruxelles

Belgium

Research Interests

Explore related searches

Professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jean-Pierre Brion is a Professor and Director of LHNN at Université Libre de Bruxelles, Belgium. His research focuses on Alzheimer's disease, particularly on the role of non-coding RNAs, gene expression, and tau propagation models. He has published extensively on the molecular mechanisms underlying Alzheimer's pathology and the potential for disease-modifying therapies.

Articles (16)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Benoît Delatour

CNRS Délégation Paris B

FRANCE

View details

Karelle Leroy

Professor

Université libre de Bruxelles

BELGIUM

View details

Charles Duyckaerts

Professor

Université Paris Descartes Faculté de Médecine

FRANCE

View details

Philippe Gailly

Professor

Université catholique de Louvain

BELGIUM

View details

Diana Kerwin

University of Texas Southwestern Medical Center

UNITED STATES

View details

Michael Gold

Chief R&D Officer

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jean-Pierre Brion

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Downregulation of hsa-miR-132 and hsa-miR-129: non-coding RNA molecular signatures of Alzheimer’s disease

Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer's disease pathology progression.

Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models

Loss of Ephaptic Contacts in the Murine Thalamus during Osmotic Demyelination Syndrome

PICALM and Alzheimer’s Disease: An Update and Perspectives

Alzheimer PHF-tau aggregates do not spread tau pathology to the brain via the Retino-tectal projection after intraocular injection in mouse models

Current directions in tau research: Highlights from Tau 2020

Regulation of PPARα by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity

A primary cilium in oligodendrocytes: a fine structure signal of repairs in thalamic Osmotic Demyelination Syndrome (ODS)

Dysregulation of Phosphoinositide 5-Phosphatases and Phosphoinositides in Alzheimer's Disease

Tau Pathology and Adult Hippocampal Neurogenesis: What Tau Mouse Models Tell us?

Alzheimer's Disease: Tau Pathology and Dysfunction of Endocytosis

The lipid phosphatase Synaptojanin 1 undergoes a significant alteration in expression and solubility and is associated with brain lesions in Alzheimer’s disease

de novo MAPT mutation G335A causes severe brain atrophy, 3R and 4R PHF-tau pathology and early onset frontotemporal dementia

The osmotic demyelination syndrome: the resilience of thalamic neurons is verified with transmission electron microscopy

Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice

Collaborators (6)

Benoît Delatour

Karelle Leroy

Charles Duyckaerts

Philippe Gailly

Diana Kerwin

Michael Gold

Make your next move.